Navigation Links
Positive results from phase 1 clinical trials of cuprindro
Date:2/15/2008

Medical Therapies Limited today announced that it has completed its first in human clinical trial of Cuprindo™ with interim results from patient diaries indicating that Cuprindo™ is safe and well tolerated.

The trial subjects, healthy volunteers, reported 100% compliance with the dosing protocol which involved application of Cuprindo™ suppositories twice daily over a seven day period. In addition, post-trial colonoscopy on the subjects uncovered healthy mucosa and no evidence of rectal inflammation or ulceration.

The safety trial was conducted in preparation for a planned efficacy study in proctitis patients.

The trial has been a success confirming our pre-clinical safety information on Cuprindo™ and it paves the way for our efficacy study in patients with proctitis, said Medical Therapies Chief Executive Officer Maria Halasz.

While the trial was not geared to assess Cuprindo™s systemic efficacy, one subject reported relief in chronic joint pain after Day 4 of the trial. Results of the full biochemical analysis of the trial assays including information on systemic absorption characteristics of Cuprindo™ are expected in the coming weeks.

Proctitis is a debilitating disease characterised by inflammation and ulceration of the colon, resulting in tiny open sores that can bleed and produce mucus. Symptoms of the disease include chronic diarrhoea, bloody stools and, in severe cases, faecal incontinence.

Current treatments such as corticosteroids and immuno-modulators can cause serious side effects and provide no relief for up to 30% of proctitis patients. A topically applied safe treatment, such as a Cuprindo™ suppository, could provide a much needed alternative for the 1 in 60 people suffering from the disease.


'/>"/>

Contact: Dr. Stephanie Williams
williams@medicaltherapies.com.au
61-292-990-311
Research Australia
Source:Eurekalert

Page: 1

Related medicine news :

1. Single reader with CAD more efficient, yields fewer false positives, and possibly more sensitive
2. HPV-positive head and neck cancer patients fare better than HPV-negative patients
3. HPV-Positive Head and Neck Cancers Fare Better
4. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
5. Seeing our spouses more negatively might be a positive
6. Abbotts Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
7. Eating out can have both positive and negative impact on obesity
8. Medco CEO Reiterates Guidance, Positive Outlook for 2008
9. Brain Turns to Positive Thoughts When Faced With Death
10. Anthracyclines improve survival in HER2-positive breast cancer patients
11. Six Positive Predictions for 2008, from SuperLife World Service
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Hospice Foundation of America Presents Webinar on 'Bereavement Camps for Kids: Benefits and Challenges' 2Health News:Independence Blue Cross Supports Pennsylvania Fitness Program with Grants to 10 Area Schools 2Health News:Independence Blue Cross Supports Pennsylvania Fitness Program with Grants to 10 Area Schools 3Health News:Some Myths About Dogs and Cats Are Not Only False - They're Dangerous! 2Health News:Lung Cancer Alliance-Georgia Hails Senate Leadership on Lung Cancer Mortality Reduction Act of 2009 2Health News:Lung Cancer Alliance-Georgia Hails Senate Leadership on Lung Cancer Mortality Reduction Act of 2009 3Health News:U.S. Bishops Urge Senators to Support Nelson-Hatch-Casey Amendment on Health Care Reform; Urge Constituents to Back it 2Health News:U.S. Bishops Urge Senators to Support Nelson-Hatch-Casey Amendment on Health Care Reform; Urge Constituents to Back it 3Health News:U.S. Bishops Urge Senators to Support Nelson-Hatch-Casey Amendment on Health Care Reform; Urge Constituents to Back it 4Health News:U.S. Bishops Urge Senators to Support Nelson-Hatch-Casey Amendment on Health Care Reform; Urge Constituents to Back it 5
Breaking Medicine Technology:Multiple Sclerosis Patient Finds Hope Through Stem Cell Treatment 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Beverage Can Stay Tabs Pose Swallowing Risk 62223 1Beverage Can Stay Tabs Pose Swallowing Risk 62223 2New Class of Platinum Based Anti Tumor Drugs Bisplatinates Demonstrates Potent Anti Tumor Activity and Ability to Overcome Resistance to Currently A 14993 1New Class of Platinum Based Anti Tumor Drugs Bisplatinates Demonstrates Potent Anti Tumor Activity and Ability to Overcome Resistance to Currently A 14993 2New Class of Platinum Based Anti Tumor Drugs Bisplatinates Demonstrates Potent Anti Tumor Activity and Ability to Overcome Resistance to Currently A 14993 3Elsevier is Re Launching 26quot 3BEmbase 26quot 3B to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 14989 1Elsevier is Re Launching 26quot 3BEmbase 26quot 3B to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 14989 2Elsevier is Re Launching 26quot 3BEmbase 26quot 3B to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 14989 3